Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Immunovant (Nasdaq: IMVT) has announced an investor webcast scheduled for September 9, 2024, at 8:00 a.m. ET to provide updates on its Graves' Disease (GD) program. The presentation will cover:
- New epidemiologic data on the potential addressable market
- Additional results from the Phase 2 study of batoclimab
- An overview of the IMVT-1402 development program in GD
Investors can register for the event through a provided link, and a live webcast will be available on Immunovant's website. A replay of the event and presentation will be accessible immediately after the webcast concludes.
Immunovant (IMVT) reported progress in its clinical programs and financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:
1. Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial
2. On track to initiate IMVT-1402 registrational program by March 31, 2025
3. Three IND applications for IMVT-1402 expected to be active by December 31, 2024
4. Cash position of $560 million as of June 30, 2024
5. R&D expenses increased to $75.5 million from $50.6 million YoY
6. Net loss of $87.2 million ($0.60 per share) compared to $73.9 million ($0.57 per share) YoY
The company aims to initiate 4-5 registrational programs for IMVT-1402 by March 2025 and clinical trials in 10 indications by March 2026.
Immunovant (Nasdaq: IMVT) reported corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2024.
The company plans to initiate 4-5 potentially registrational studies for its lead asset IMVT-1402 in various therapeutic areas by March 31, 2025. Topline data from the batoclimab Myasthenia Gravis study is expected in the same timeframe.
R&D expenses for Q4 increased to $66.1M, and net loss widened to $75.3M. For the fiscal year, R&D expenses rose to $212.9M, and net loss was $259.3M.
IMVT's cash position was approximately $635M as of March 31, 2024. They hold a new U.S. patent extending until June 2043.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.